NCT03006367

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

An Open-label, Single Ascending Dose, Pharmacokinetic and Tolerability Study of NFC-1 in Children and Adolescents (Ages 6-17 Years) With Attention Deficit Hyperactivity Disorder

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Aevi Genomic Medicine, LLC, a Cerecor company · Industry
• Sex: All
• Age: 6 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

This is a open-label, single ascending dose, pharmacokinetic, and tolerability study of NFC-1 in Children and Adolescents (Ages 6-17 Years) with ADHD.

Conditions

• Attention Deficit Disorder With Hyperactivity

Interventions

Type	Name	Description
DRUG	NFC-1 100 mg
DRUG	NFC-1 200 mg
DRUG	NFC-1 400 mg
DRUG	NFC-1 800 mg

Timeline

• Start date: 2017-01-07
• Primary completion: 2017-02-26
• Completion: 2017-03-06
• First posted: 2016-12-30
• Last updated: 2021-07-06

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study